BioCatalyst

Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg — catalyst calendar

1 verified catalyst event(s) referencing Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08-05
in 1mo
ESTIMATED
 READOUT
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Stud
Phase 2 · Chronic Obstructive Pulmonary Disease
 Verona Pharma, Inc., a subsidiary Ensifentrine 3 mg, Glycopyrrolate 21.25 ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.